Cleveland Biolabs (NASDAQ:CBLI) will report earnings before markets open on Tuesday, August 13th. Cleveland Biolabs, Inc. develops pharmaceuticals. The Company develops drugs to protect humans from exposure to radiation.
Here is your Cheat Sheet to Cleveland Biolabs Earnings:
Earnings Expectations: Analysts expect earnings of $-0.16 per share on revenues of $1.48 million.
Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.15 to a loss $0.14. For the current year, the average estimate is a loss of $0.58, which is worse than the estimate ninety days ago.
Here’s how Cleveland Biolabs has been performing on an annual basis:
|Revenue ($) in millions||5||14||15||9||4|
|Diluted EPS ($)||-1.13||-0.82||-1.01||-0.12||-0.49|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012||Mar. 31, 2013|
|Revenue ($) in millions||0.26||0.22||2.16||1.37|
|Diluted EPS ($)||-0.14||-0.30||0.07||-0.22|
Cleveland Biolabs has beat analyst estimates 1 time in the past four quarters. This is not consistent enough to get bullish yet.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)